300006.SZ
Chongqing Lummy Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 9.92
+19.95%Oct 23, 2026, 08:07 UTC
Laimei Pharmaceutical reported third-quarter 2026 revenue of 175 million yuan, down 14.19% year over year, net loss of 7.2645 million yuan, and adjusted net loss of 14.0698 million yuan; for the first nine months of 2026, revenue was 525 million yuan, down 9.58%, net loss was 30.682 million yuan, and adjusted net loss was 39.8448 million yuan.
Source:Oct 8, 2026, 08:37 UTC
Laimei Pharmaceutical plans to publicly list for sale land-use rights and buildings at 8 Yueji Road, Nan'an District, Chongqing, with a minimum asking price of RMB 31.232 million.
Sep 14, 2026, 07:57 UTC
Chongqing Lummy Longyu Pharmaceutical, a wholly owned subsidiary of Lummy Pharmaceutical, received approval from China's National Medical Products Administration to produce and market finerenone as an active pharmaceutical ingredient in China.
Source:Aug 10, 2026, 07:44 UTC
Lemei Pharmaceutical obtained the Drug Registration Certificate for Acetylcysteine Solution for Inhalation (3ml:0.3g) approved by the National Medical Products Administration, valid until August 3, 2031, for the treatment of respiratory diseases.
Jul 2, 2026, 07:45 UTC
Lummy Pharmaceutical's industrial investment fund Saifu Health plans to liquidate and dissolve.